Yaohua Zhang

Publications

• Published on 3/29/2023

  Zhang Y, Chu C, Beckman RA, Gao L, Laird G, Yi B. A confirmatory basket design considering non-inferiority and superiority testing. J Biopharm Stat. 2024 Mar; 34(2):205-221. PMID: 36988397.

  Read At: PubMed

• Published on 9/14/2022

  Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C, Majoor C, Bruinsma BG, Moskowitz S, Prieto-Centurion V, Van Brunt K, Zhang Y, Quittner A. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2023 Jan; 22(1):119-123. PMID: 36114142.

  Read At: PubMed

• Published on 8/29/2022

  Viswanathan L, Bachman E, Tian S, Ahluwalia N, Zhang Y, Bernstein HS, Panorchan P. Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2022 Nov; 47(6):817-825. PMID: 36036885.

  Read At: PubMed

• Published on 8/26/2021

  Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 Aug 26; 385(9):815-825. PMID: 34437784.

  Read At: PubMed

• Published on 10/31/2019

  Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 Nov 23; 394(10212):1940-1948. PMID: 31679946.

  Read At: PubMed